Who is eligible for a consultation?
Paxlovid is intended for those with mild to moderate COVID-19 who are at high-risk for progression to severe COVID-19, and who are within 5 days of symptom onset. Learn more about Paxlovid on the manufacturer’s website, and review the patient and healthcare provider fact sheets for more information.
People who have had symptoms more than five days, who may be pregnant, or who are not at high risk for severe illness (based on age or medical history), may not be eligible for Paxlovid through this program.
A consultation for COVID-19 antiviral treatment is currently only available through Color to those who are 18 or older. If you are under 18, please talk to a healthcare provider about treatment options.
Eligibility may also be restricted depending on your Color program sponsor’s terms. Eligibility through Color’s partnership with Massachusetts is limited to persons whose current address is in Massachusetts and pharmacy products are only shipped to valid addresses in Massachusetts.
What treatment options for COVID-19 will be considered?
Clinicians will be evaluating whether a patient should be given a prescription for the COVID-19 antiviral treatment Paxlovid. If you are interested in other treatment options for COVID-19, please seek care from your healthcare provider.
What is Paxlovid?
Paxlovid has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS CoV-2 viral testing, and who are at high-risk for progression to severe COVID-19, including hospitalization or death.
If Paxlovid is appropriate, treatment should be initiated as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset. Paxlovid is not for people that have a history of allergy to nirmatrelvir or ritonavir or other components of these drugs, and it is not for people taking certain other drugs. Paxlovid may cause side effects, some of which may be serious and unexpected. Learn more about Paxlovid on the manufacturer’s website, at https://www.covid19oralrx-patient.com, and review the patient and healthcare provider fact sheets for more information.
The emergency use of Paxlovid is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb3(b)(1), unless the declaration is terminated or authorization revoked sooner.
Will I have to pay for the consultation or COVID-19 antiviral treatment?
No. The Color services, including clinical consultation and mail order pharmacy service, are made available at no cost to you. The cost of Paxlovid is currently covered by the federal government (subject to change).
If you choose to use a local pharmacy, you are responsible if there are any associated costs.